FDA Approves Subcutaneous Atezolizumab and Hyaluronidase-tqjs for Use in All Indications of IV Atezolizumab
The FDA has approved subcutaneous atezolizumab for use in all indications as the intravenous formulation.
Related Articles
Neratinib Joins NCCN Guidelines for HER2-Mutated Cervical Cancer
The NCCN Guidelines have been updated to include neratinib for HER2-mutated recurrent/metastatic cervical cancer in the second line or later.
Key Considerations for the Evolving Treatment Landscape for Relapsed/Refractory Follicular Lymphoma
A panelist discusses how various antibody-drug conjugates, including polatuzumab vedotin, pinatuzumab vedotin, and loncastuximab, have been studied in combination with rituximab for relapsed/refractory follicular lymphoma.…
Community Practice Training During Fellowship Often Falls Short
A hematology fellow discusses findings from 2 surveys he coauthored, which sought to identify gaps in community practice training during hematology/oncology fellowship.
FDA Approves Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors
The FDA has approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult solid tumor nivolumab (Opdivo) indications.
Advancing Cell Therapy Research, Discovery & Innovation : Oncology Times
An abstract is unavailable.
Oncogene Analysis Identifies Clinically Relevant Gene Copy Number Gain Thresholds in NSCLC: With Alec Watson, MD
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1
Yang et al. report that the intracellular CD28 in triple negative breast cancer (TNBC) cells promotes PD-L1-mediated immune escape. Inhibition of CD28 in cancer cells decreases…
Many older men with prostate cancer and limited life expectancy are overtreated
More men with limited life expectancy and certain localized prostate cancers have received definitive treatment over the past 2 decades despite shifts toward active surveillance,…
Evaluating organ-specific responses to ADCs in metastatic breast cancer
Neelima Vidula, MD, Massachusetts General Hospital, Boston, MA, comments a retrospective analysis of organ site-specific responses to sacituzumab govitecan and trastuzumab deruxtecan in metastatic breast…
Sasanlimab Plus BCG Demonstrates EFS Benefit in NMIBC
Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.